Parthenogenic oocyte activation
US5496720A · kind A · utility
63Cited by
2References
25Claims
0Family size
Inventors
Key dates
| Filing date | Feb 10, 1993 |
| Grant date | Mar 5, 1996 |
| Priority date | — |
| Expiry date | Feb 10, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/999
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A process of parthenogenic activation of mammalian oocytes which includes increasing intercellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca.sup.2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.